Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 124, Issue -, Pages 41-50Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2018.02.003
Keywords
Venous thromboembolism; Hematological malignancies; Low molecular weight heparin; Anticoagulant treatment; Prophylaxis; Chemotherapy; Thrombocytopenia; Bleeding
Categories
Ask authors/readers for more resources
Venous Thromboembolism (VTE) frequently complicates the course of hematologic malignancies (HM) and its incidence is similar to that observed in high-risk solid tumors. Despite that, phannacologic prophylaxis and treatment of VTE in patients with HM is challenging, mainly because a severe thrombocytopenia frequently complicates the course of treatments or may be present since diagnosis, thus increasing the risk of bleeding. Therefore, in this setting, safe and effective methods of VTE prophylaxis and treatment have not been well defined and hematologists generally refer to guidelines produced for cancer patients that give indications on anticoagulation in patients with thrombocytopenia. In this review, besides to summarize the incidence and the available data on prophylaxis and treatment of VTE in HM, we give some advices on how to use antithrombotic drugs in patients with HM according to platelets count.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available